YSPSL for Prevention of Delayed Graft Function Part A

Status Completed

Clinical Trial Summary

Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant DGF. PSGL-1 is a ligand for P-, E-, and L-selectin. It has been reported that that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both cytokines and tissue damage associated with ischemia reperfusion and to improve renal function post-transplant. Therefore, the current phase I/II clinical study is designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.

Clinical Trial Description

This will be a multicenter, single-dose, dose-escalation study. The study will be in 2 parts: the first, Part A, will be an open label evaluation of single doses of four dose cohorts and the second, Part B will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of two dose cohorts. Patients who are undergoing cadaveric kidney transplantation and are at risk for development of DGF, based upon known risk factors, will be eligible to participate in the study. A maximum of 24 patients will be enrolled in Part A of the study. 60 patients will be enrolled in Part B. ;

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Delayed Graft Function

Clinical Trial Details

NCT number	NCT00298181
Study type	Observational
Source	Y's Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 2005
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02312115` - Delayed Renal Allograft Function and Furosemide Treatment	Phase 2
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Completed	`NCT02346968` - Evaluation of CAF22 After Renal Transplantation
Completed	`NCT01794663` - Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function	Phase 2
Not yet recruiting	`NCT05166460` - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation	N/A
Recruiting	`NCT03071536` - Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation	N/A
Not yet recruiting	`NCT05513807` - Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant	Phase 3
Recruiting	`NCT04005469` - Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT01848249` - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting	`NCT02474667` - Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney	Phase 3
No longer available	`NCT02026934` - CliniMACS® CD34+ Reagent System for Expanded Access Use	N/A
Terminated	`NCT00217152` - A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors	Phase 4
Recruiting	`NCT05430620` - Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys	Phase 3
Completed	`NCT03864926` - Envarsus in Delayed Graft Function (E-DGF)	Phase 4
Recruiting	`NCT06367205` - Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations	N/A
Completed	`NCT02610296` - QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant	Phase 3
Active, not recruiting	`NCT02568696` - Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
Recruiting	`NCT01837043` - Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function	Phase 2
Terminated	`NCT01878786` - A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys	Phase 2/Phase 3
Active, not recruiting	`NCT01395719` - Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function	N/A